Literature DB >> 23140977

Prevalence, incidence, and classification of chronic fatigue syndrome in Olmsted County, Minnesota, as estimated using the Rochester Epidemiology Project.

Ann Vincent1, Dana J Brimmer, Mary O Whipple, James F Jones, Roumiana Boneva, Brian D Lahr, Elizabeth Maloney, Jennifer L St Sauver, William C Reeves.   

Abstract

OBJECTIVE: To estimate the prevalence and incidence of chronic fatigue syndrome in Olmsted County, Minnesota, using the 1994 case definition and describe exclusionary and comorbid conditions observed in patients who presented for evaluation of long-standing fatigue. PATIENTS AND METHODS: We conducted a retrospective medical record review of potential cases of chronic fatigue syndrome identified from January 1, 1998, through December 31, 2002, using the Rochester Epidemiology Project, a population-based database. Patients were classified as having chronic fatigue syndrome if the medical record review documented fatigue of 6 months' duration, at least 4 of 8 chronic fatigue syndrome-defining symptoms, and symptoms that interfered with daily work or activities. Patients not meeting all of the criteria were classified as having insufficient/idiopathic fatigue.
RESULTS: We identified 686 potential patients with chronic fatigue, 2 of whom declined consent for medical record review. Of the remaining 684 patients, 151 (22%) met criteria for chronic fatigue syndrome or insufficient/idiopathic fatigue. The overall prevalence and incidence of chronic fatigue syndrome and insufficient/idiopathic fatigue were 71.34 per 100,000 persons and 13.16 per 100,000 person-years vs 73.70 per 100,000 persons and 13.58 per 100,000 person-years, respectively. The potential cases included 482 patients (70%) who had an exclusionary condition, and almost half the patients who met either criterion had at least one nonexclusionary comorbid condition.
CONCLUSION: The incidence and prevalence of chronic fatigue syndrome and insufficient/idiopathic fatigue are relatively low in Olmsted County. Careful clinical evaluation to identify whether fatigue could be attributed to exclusionary or comorbid conditions rather than chronic fatigue syndrome itself will ensure appropriate assessment for patients without chronic fatigue syndrome.
Copyright © 2012 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23140977      PMCID: PMC3518652          DOI: 10.1016/j.mayocp.2012.08.015

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  24 in total

1.  The prevalence of chronic fatigue syndrome in Nigeria.

Authors:  Mary Gloriac C Njoku; Leonard A Jason; Susan R Torres-Harding
Journal:  J Health Psychol       Date:  2007-05

2.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

3.  The prevalence of chronic fatigue syndrome in Iceland - a national comparison by gender drawing on four different criteria.

Authors:  Eiríkur Líndal; Jón G Stefánsson; Sverrir Bergmann
Journal:  Nord J Psychiatry       Date:  2002       Impact factor: 2.202

4.  Prognosis of chronic fatigue in a community-based sample.

Authors:  Renee R Taylor; Leonard A Jason; Carrie J Curie
Journal:  Psychosom Med       Date:  2002 Mar-Apr       Impact factor: 4.312

5.  The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group.

Authors:  K Fukuda; S E Straus; I Hickie; M C Sharpe; J G Dobbins; A Komaroff
Journal:  Ann Intern Med       Date:  1994-12-15       Impact factor: 25.391

6.  Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester epidemiology project.

Authors:  Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Walter A Rocca
Journal:  Am J Epidemiol       Date:  2011-03-23       Impact factor: 4.897

7.  CFS: A Review of Epidemiology and Natural History Studies.

Authors:  Leonard A Jason; Nicole Porter; Molly Brown; Valerie Anderson; Abigail Brown; Jessica Hunnell; Athena Lerch
Journal:  Bull IACFS ME       Date:  2009

8.  The epidemiology of chronic fatigue in San Francisco.

Authors:  L Steele; J G Dobbins; K Fukuda; M Reyes; B Randall; M Koppelman; W C Reeves
Journal:  Am J Med       Date:  1998-09-28       Impact factor: 4.965

9.  Prevalence of chronic fatigue syndrome in metropolitan, urban, and rural Georgia.

Authors:  William C Reeves; James F Jones; Elizabeth Maloney; Christine Heim; David C Hoaglin; Roumiana S Boneva; Marjorie Morrissey; Rebecca Devlin
Journal:  Popul Health Metr       Date:  2007-06-08

10.  A population-based study of the clinical course of chronic fatigue syndrome.

Authors:  Rosane Nisenbaum; James F Jones; Elizabeth R Unger; Michele Reyes; William C Reeves
Journal:  Health Qual Life Outcomes       Date:  2003-10-03       Impact factor: 3.186

View more
  14 in total

1.  Chronic Multisymptom Illness Among Iraq/Afghanistan-Deployed US Veterans and Their Healthcare Utilization Within the Veterans Health Administration.

Authors:  April F Mohanty; Lisa M McAndrew; Drew Helmer; Matthew H Samore; Adi V Gundlapalli
Journal:  J Gen Intern Med       Date:  2018-09       Impact factor: 5.128

2.  Structural brain changes versus self-report: machine-learning classification of chronic fatigue syndrome patients.

Authors:  Landrew S Sevel; Jeff Boissoneault; Janelle E Letzen; Michael E Robinson; Roland Staud
Journal:  Exp Brain Res       Date:  2018-05-30       Impact factor: 1.972

3.  Defining Essential Features of Myalgic Encephalomyelitis and Chronic Fatigue Syndrome.

Authors:  Leonard A Jason; Madison Sunnquist; Abigail Brown; Jordan Reed
Journal:  J Hum Behav Soc Environ       Date:  2015-05-06

4.  Chronic Fatigue Syndrome prevalence is grossly overestimated using Oxford criteria compared to Centers for Disease Control (Fukuda) criteria in a U.S. population study.

Authors:  James N Baraniuk
Journal:  Fatigue       Date:  2017-07-21

Review 5.  Case definitions for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): a systematic review.

Authors:  Kjetil Gundro Brurberg; Marita Sporstøl Fønhus; Lillebeth Larun; Signe Flottorp; Kirsti Malterud
Journal:  BMJ Open       Date:  2014-02-07       Impact factor: 2.692

6.  Longitudinal follow-up of employment status in patients with chronic fatigue syndrome after mononucleosis.

Authors:  Morten Nyland; Halvor Naess; Jon Steinar Birkeland; Harald Nyland
Journal:  BMJ Open       Date:  2014-11-26       Impact factor: 2.692

7.  Two age peaks in the incidence of chronic fatigue syndrome/myalgic encephalomyelitis: a population-based registry study from Norway 2008-2012.

Authors:  Inger Johanne Bakken; Kari Tveito; Nina Gunnes; Sara Ghaderi; Camilla Stoltenberg; Lill Trogstad; Siri Eldevik Håberg; Per Magnus
Journal:  BMC Med       Date:  2014-10-01       Impact factor: 8.775

8.  A pilot registry of unexplained fatiguing illnesses and chronic fatigue syndrome.

Authors:  Dana J Brimmer; Elizabeth Maloney; Rebecca Devlin; James F Jones; Roumiana Boneva; Caryn Nagler; Lisa LeRoy; Scott Royal; Hao Tian; Jin-Mann S Lin; Jennifer Kasten; Elizabeth R Unger
Journal:  BMC Res Notes       Date:  2013-08-02

Review 9.  Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME).

Authors:  Eun-Jin Lim; Yo-Chan Ahn; Eun-Su Jang; Si-Woo Lee; Su-Hwa Lee; Chang-Gue Son
Journal:  J Transl Med       Date:  2020-02-24       Impact factor: 5.531

10.  Elevated blood lactate in resting conditions correlate with post-exertional malaise severity in patients with Myalgic encephalomyelitis/Chronic fatigue syndrome.

Authors:  Alaa Ghali; Carole Lacout; Maria Ghali; Aline Gury; Anne-Berengere Beucher; Pierre Lozac'h; Christian Lavigne; Geoffrey Urbanski
Journal:  Sci Rep       Date:  2019-12-11       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.